Shield Therapeutics plc (LON:STX – Get Free Report) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 2.72 ($0.03) and traded as low as GBX 2.27 ($0.03). Shield Therapeutics shares last traded at GBX 2.40 ($0.03), with a volume of 9,722,382 shares changing hands.
Shield Therapeutics Price Performance
The firm has a market capitalization of £19.07 million, a P/E ratio of -60.98 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The stock has a 50 day moving average of GBX 2.72 and a two-hundred day moving average of GBX 3.20.
Shield Therapeutics Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Recommended Stories
- Five stocks we like better than Shield Therapeutics
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Stock Market Upgrades: What Are They?
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Do ETFs Pay Dividends? What You Need to Know
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
